Here are 1-2 brief analogies for Cadrenal Therapeutics (CVKD):

• Cadrenal Therapeutics is like **BioMarin, but focused on creating a specialized blood thinner for patients with end-stage kidney disease and irregular heartbeats.**
• They aim to be the **'Eliquis for end-stage kidney disease patients with atrial fibrillation,'** developing a tailored anticoagulant for this vulnerable group where safe options are lacking.

• Tecarfarin: A novel, oral, once-daily anticoagulant, in Phase 3 development, for the prevention of systemic thromboembolism in patients with end-stage renal disease and atrial fibrillation.

Cadrenal Therapeutics (CVKD) is a clinical-stage biopharmaceutical company focused on developing its drug candidate, tecarfarin. As such, it does not currently have major customers in the traditional sense of selling an approved product to individuals, healthcare providers, or pharmacies.

However, the company has entered into a licensing agreement that can be considered a form of business-to-business relationship generating revenue or partnership. The major identified partner in this capacity is:

• Lee’s Pharmaceutical Holdings Limited (listed in Hong Kong, HKEX: 00950) - Cadrenal Therapeutics has licensed out the rights to tecarfarin for several Asian markets, including China, to Lee’s Pharmaceutical Holdings Limited. This company is developing tecarfarin as an anti-thrombotic for patients with mechanical heart valves.

Quang Pham, Chairman & Chief Executive Officer

Mr. Pham formed Cadrenal Therapeutics and has served as its Chief Executive Officer since its inception. He previously served as Chairman & CEO and co-founder of Espero BioPharma, Inc., which was the previous sponsor of the tecarfarin Investigational New Drug (IND). He also served as a consultant to HESP LLC, the assignee for Espero to Horizon Technology Finance.

Matthew Szot, Chief Financial Officer and Co-Founder

Mr. Szot has served as Cadrenal Therapeutics' Chief Financial Officer since May 2022. From March 2010 to November 2021, he served as Executive Vice President and Chief Financial Officer of S&W Seed Company, a Nasdaq-listed agricultural seed biotechnology company. Since September 2020, Mr. Szot has served on the Board of Directors and as Chairman of the Audit and Compensation Committees of INVO Bioscience, Inc., a Nasdaq-listed commercial-stage fertility company. He was also the Chief Financial Officer for Cardiff Partners, LLC, a strategic consulting company providing executive financial services to various publicly traded and privately held companies from 2007 until 2011.

James Ferguson, M.D., FACC, FAHA, Chief Medical Officer

Dr. Ferguson joined Cadrenal Therapeutics in February 2025 as Chief Medical Officer, bringing over 25 years of leadership and deep expertise in clinical development within the cardiovascular field. Before joining Cadrenal, he served as Chief Medical Officer at Matinas BioPharma. His prior experience includes serving as Head of U.S. Cardiovascular Medical Affairs at Amgen and holding several senior positions at AstraZeneca.

Jeff Cole, Chief Operating Officer

Mr. Cole brings over 25 years of experience in global pharmaceutical manufacturing and commercial operations, finance, and corporate development. Since August 2010, he has served as Principal of J. Scott Capital, LLC, a firm that provides executive and capital resources to emerging companies.

Matthew Boxer, Ph.D., MBA

Dr. Boxer has more than 18 years of experience in drug discovery, development, and corporate strategy. Prior to joining Cadrenal, Dr. Boxer co-founded Veralox Therapeutics in 2017 and served as its Chief Operating Officer, where he was responsible for corporate strategy, governance, finance, and operations.

Risk of Insufficient Funding and Going Concern Doubts

Cadrenal Therapeutics has a history of operating losses and anticipates continued substantial losses, with its independent registered public accounting firm expressing substantial doubt about its ability to continue as a going concern. The company's current cash and offering proceeds will only fund operations for a limited time and are insufficient to fully fund the planned pivotal Phase 3 clinical trial for tecarfarin, necessitating additional capital raises for its initiation and completion.

Clinical Development and Regulatory Approval Risk for Tecarfarin

The company's success is entirely dependent on the successful completion of Phase 3 clinical trials and subsequent FDA approval of tecarfarin. There is no assurance that the FDA will accept the company's Phase 3 trial design, even if submitted using a previously proposed protocol. Although tecarfarin has Orphan Drug Designation, this status does not guarantee FDA approval or marketing exclusivity.

Intellectual Property Protection and Freedom to Operate Risk

Cadrenal Therapeutics holds two U.S. patents for tecarfarin, which are currently set to expire in 2024, although the company expects to seek extensions. Critically, the company has not yet conducted a freedom-to-operate analysis. This lack of analysis means there is no certainty that the company will not face third-party legal claims, liabilities, or litigation when developing, manufacturing, and marketing products using its tecarfarin technology.

The addressable market for Cadrenal Therapeutics' main product, tecarfarin, is approximately 150,000 patients in the U.S. This market comprises individuals with end-stage renal disease (ESRD) and atrial fibrillation (AFib).

1. Milestone Payments from Asian Licensing Agreement: Cadrenal Therapeutics has licensed the rights to tecarfarin for several Asian markets, including China, to Lee’s Pharmaceutical Holdings Limited. Lee’s Pharmaceutical is currently preparing for its Phase 2 trial of tecarfarin. As Lee's Pharmaceutical advances tecarfarin through clinical development in these territories, Cadrenal Therapeutics is expected to receive milestone payments, which would contribute to revenue growth.
2. Advancement of the U.S. Phase 3 Clinical Program for Tecarfarin: The company intends to commence its pivotal Phase 3 clinical trial for tecarfarin in the second half of 2023, assuming FDA acceptance of its trial design. While not generating direct product revenue within the 2-3 year timeframe, successful initiation, patient enrollment, and positive progress in this critical trial would significantly de-risk the asset, enhance its valuation, and pave the way for eventual regulatory approval and commercialization. This progress is a fundamental driver for future revenue potential.
3. New Strategic Partnerships and Licensing Agreements: Cadrenal Therapeutics has indicated a need to raise additional capital to fully fund its planned pivotal Phase 3 clinical trial. Securing new strategic partnerships or additional licensing agreements for tecarfarin in other regions or for different indications could provide upfront payments, research and development funding, and potential future royalties, thereby contributing to the company's revenue base and funding its continued development.